Deutsche Bank’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-310
| Closed | -$4.78K | – | 3638 |
|
|
2024
Q1 | $4.78K | Hold |
310
| – | – | ﹤0.01% | 3564 |
|
|
2023
Q4 | $8.68K | Sell |
310
-2,441
| -89% | -$64.1K | ﹤0.01% | 3543 |
|
|
2023
Q3 | $131K | Buy |
2,751
+328
| +14% | +$25K | ﹤0.01% | 3033 |
|
|
2023
Q2 | $232K | Sell |
2,423
-638
| -21% | -$69.4K | ﹤0.01% | 2797 |
|
|
2023
Q1 | $347K | Buy |
3,061
+687
| +29% | +$74.3K | ﹤0.01% | 2704 |
|
|
2022
Q4 | $266K | Buy |
2,374
+800
| +51% | +$107K | ﹤0.01% | 2800 |
|
|
2022
Q3 | $202K | Sell |
1,574
-427
| -21% | -$43.7K | ﹤0.01% | 2942 |
|
|
2022
Q2 | $137K | Sell |
2,001
-807
| -29% | -$69.5K | ﹤0.01% | 3366 |
|
|
2022
Q1 | $399K | Sell |
2,808
-11,191
| -80% | -$1.72M | ﹤0.01% | 2886 |
|
|
2021
Q4 | $2.33M | Buy |
13,999
+10,072
| +256% | +$1.6M | ﹤0.01% | 1902 |
|
|
2021
Q3 | $547K | Buy |
3,927
+1,579
| +67% | +$309K | ﹤0.01% | 2966 |
|
|
2021
Q2 | $1.12M | Sell |
2,348
-798
| -25% | -$337K | ﹤0.01% | 2695 |
|
|
2021
Q1 | $1.3M | Buy |
3,146
+866
| +38% | +$399K | ﹤0.01% | 2503 |
|
|
2020
Q4 | $1.12M | Buy |
2,280
+832
| +57% | +$487K | ﹤0.01% | 2365 |
|
|
2020
Q3 | $820K | Buy |
1,448
+280
| +24% | +$93.1K | ﹤0.01% | 2326 |
|
|
2020
Q2 | $111K | Buy |
1,168
+548
| +88% | +$48.1K | ﹤0.01% | 3389 |
|
|
2020
Q1 | $45K | Sell |
620
-37
| -6% | -$2.48K | ﹤0.01% | 3595 |
|
|
2019
Q4 | $44K | Buy |
657
+146
| +29% | +$10.8K | ﹤0.01% | 4026 |
|
|
2019
Q3 | $40K | Sell |
511
-239
| -32% | -$15.8K | ﹤0.01% | 4049 |
|
|
2019
Q2 | $46K | Sell |
750
-419
| -36% | -$39.8K | ﹤0.01% | 4543 |
|
|
2019
Q1 | $159K | Buy |
1,169
+31
| +3% | +$3.78K | ﹤0.01% | 4121 |
|
|
2018
Q4 | $102K | Sell |
1,138
-1,471
| -56% | -$206K | ﹤0.01% | 4215 |
|
|
2018
Q3 | $396K | Buy |
2,609
+44
| +2% | +$7.12K | ﹤0.01% | 3904 |
|
|
2018
Q2 | $441K | Sell |
2,565
-6,218
| -71% | -$1.02M | ﹤0.01% | 3908 |
|
|
2018
Q1 | $1.29M | Sell |
8,783
-2,577
| -23% | -$494K | ﹤0.01% | 3165 |
|
|
2017
Q4 | $2.3M | Buy |
11,360
+6,744
| +146% | +$1.39M | ﹤0.01% | 2627 |
|
|
2017
Q3 | $1.48M | Sell |
4,616
-4,482
| -49% | -$1.23M | ﹤0.01% | 2744 |
|
|
2017
Q2 | $2.05M | Sell |
9,098
-3,617
| -28% | -$743K | ﹤0.01% | 2543 |
|
|
2017
Q1 | $2.86M | Sell |
12,715
-4,767
| -27% | -$967K | ﹤0.01% | 2023 |
|
|
2016
Q4 | $3.46M | Buy |
17,482
+204
| +1% | +$44.5K | ﹤0.01% | 1903 |
|
|
2016
Q3 | $4.25M | Buy |
17,278
+16,674
| +2,761% | +$5.85M | ﹤0.01% | 1850 |
|
|
2016
Q2 | $349K | Buy |
604
+171
| +39% | +$100K | ﹤0.01% | 3479 |
|
|
2016
Q1 | $229K | Buy |
433
+326
| +305% | +$170K | ﹤0.01% | 3595 |
|
|
2015
Q4 | $75K | Sell |
107
-13
| -11% | -$8.54K | ﹤0.01% | 4195 |
|
|
2015
Q3 | $70K | Sell |
120
-854
| -88% | -$697K | ﹤0.01% | 4272 |
|
|
2015
Q2 | $808K | Buy |
+974
| New | +$850K | ﹤0.01% | 3102 |
|
Other funds holding MCRB
FP
TCM
Deutsche Bank's MCRB Position: Q2 2024 in Review
Deutsche Bank sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 310 shares — an estimated $4.78K sold.
Deutsche Bank first reported a position in MCRB in Q2 2015 and held it in 36 quarters. The position peaked at $4.25M in Q3 2016. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.
- Deutsche Bank reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
- Deutsche Bank sold 310 Seres Therapeutics shares in Q2 2024, an estimated $4.78K.
- Deutsche Bank first reported a position in Seres Therapeutics in Q2 2015 and held it in 36 quarters.
- Deutsche Bank's Seres Therapeutics position peaked at $4.25M in Q3 2016.
- 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.
Based on Deutsche Bank's 13F filing for Q2 2024, filed 14 Aug 2024.